Form 4: Shelley Chu, Director at HilleVax, Inc., Reports Stock Option Grant

Director Shelley Chu reports the acquisition of stock options in HilleVax, Inc. pursuant to the non-employee director compensation program.

Summary

• Shelley Chu, a director at HilleVax, Inc. (HLVX), filed a Form 4 with the SEC.
• The filing reports the grant of stock options to Chu on June 6, 2024.
• Chu acquired 22,500 stock options with an exercise price of $13.75.
• The options vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, contingent on continued service as a director.
• The options expire on June 5, 2034.
• Following the transaction, Chu directly owns 22,500 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a routine director compensation event, which is generally viewed neutrally to positively as it aligns director and shareholder interests.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the board.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common form of compensation for directors of publicly traded companies, aligning their interests with shareholders and incentivizing company performance.

Comparison to Industry Standards

• Director compensation packages, including stock options, vary widely across the biotechnology industry depending on company size, stage of development, and board composition.
• Comparing HilleVax's director compensation to peers like Moderna, BioNTech, or Novavax would provide a more detailed benchmark, considering factors such as market capitalization and revenue generation.
• Typically, vesting schedules are structured to incentivize long-term commitment, with annual or milestone-based vesting being common.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's long-term success.
• The director benefits from the potential future value of the stock options.

Key Dates

Keywords

Form 4, HilleVax, Stock Options, Director, Shelley Chu, HLVX, Grant